Bildkälla: Stockfoto

Alzecure Pharma: First Patient in – phase II trial with ACD440 - Redeye

Redeye is positive to the recent progress with neuropathic pain candidate ACD440 and provides a short comment.

Redeye is positive to the recent progress with neuropathic pain candidate ACD440 and provides a short comment.
Börsvärldens nyhetsbrev
ANNONSER